RNAimmune secures $27M Series A to advance mRNA therapeutics and vaccines; Artivila Biopharma, Biosion, REC Bio
Elise Mak · 03/31/2022
mRNA specialist RNAimmune has gained $27 million from a Series A round to support its R&D in mRNA vaccine and drug discovery to tackle infectious diseases, cancer and rare diseases. More news from Artivila Biopharma, Biosion, REC Bio, Merck KGaA, Xynomic Pharma, Keymed Bio and Innovent.
Everest gains global rights to oral COVID-19 drugs; REC Bio - News of the day
Elise Mak · 01/14/2022
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement